Genome Web: Oncology community sees potential for patient harm in FDA ok of 23andMe BRCA test
Rating: 5.0 Stars
- Headline matches article and has an accurate lede. The article is well-balanced and discusses disagreements in the field.
- The article is well sourced and uses multiple outside sources.
- It is clearly written and portrays the novelty appropriately.
- Reporting is factually correct and uses appropriate scientific terminology.
- Performed a critical evaluation of the topic.
- Statistics are accurately conveyed.
Genome Web: FDA authorizes 23andme DTC test report for three BRCA mutations
Rating: 3.5 Stars
- Headline matches the content of the FDA statement. Lede is not exaggerated. The article is well-balanced.
- There is no outside sourcing. Sources cited are part of the FDA press release.
- The writing is clear and the novelty of the research is portrayed accurately.
- The reporting is factually correct. Although, like the FDA statement, the article states that there are well over 1,000 mutations, rather than 5,400+ (although technically accurate, this number is grossly underestimated).
- Statement was not critically evaluated.
- Terminology is correctly used and statistics are accurately portrayed.
CNN Money: 23andMe gets FDA approval for at-home breast cancer risk test
Rating: 2.5 Stars
- Headline matches content although “at-home” is misleading (testing is done at 23andMe lab). The lede is accurate. The article portrays some aspects of controversy surrounding this topic. Little actual information is conveyed.
- The only sources are from 23andme. The writing is easy to read and the novelty of the testing is clear.
- The article lacks critical evaluation of the research and provides little factual information. What is presented is accurate. The terminology used is sparse but accurate. Statistics included are accurate.